← All trials
NCT05548270
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 23, 2022
- Primary completion
- Dec 15, 2022
- Completion date
- Dec 15, 2022
- First posted
- Sep 21, 2022
- Last posted
- Sep 21, 2022
- Enrollment
- 500
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Repurposed Therapeutics, Inc.Lead sponsor
- Defender Pharmaceuticals, Inc.Study director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.